Relay Therapeutics heads into its Q2 earnings release tonight with a striking divergence: short sellers have been covering aggressively, even as the analyst community has turned unanimously bullish.
The short-interest picture tells the clearest story. Bearish positioning has collapsed by roughly 15% over the past month, dropping from a peak near 47 million shares in mid-July to just under 39.3 million — 22.7% of the float. That retreat is significant. At the July highs, short interest was at its most extreme; the recent covering wave suggests bears are reducing exposure ahead of the print rather than pressing their bets. Borrow conditions support that read: availability has loosened considerably to 248%, up nearly 20% on the week, and the cost to borrow has eased to just 0.45%, near its lowest level in months. There is no squeeze pressure in the lending market. The ORTEX short score, while still elevated at 73, has drifted down from 76 in late July — another signal that the most aggressive short positioning has passed its peak.
Options positioning has also normalised sharply. The put/call ratio is running at 1.0, well below its 20-day average of 1.54 — meaning options traders have rotated from heavy downside hedging toward a more balanced stance. Earlier in the summer, the PCR was above 4.0, reflecting deep scepticism; the reversal to parity in the past few weeks is the most notable options shift in the setup. That compression coincides almost exactly with a wave of bullish analyst moves: Goldman Sachs raised its target to $31 on July 21, Canaccord Genuity and JP Morgan both initiated with Buy/Overweight ratings in July at $29 and $28 respectively. The consensus mean target of $26.31 sits 33% above the current price of $19.75, and the analyst recommendation divergence factor ranks in the 99th percentile — meaning the Street is more uniformly bullish on RLAY relative to peers than almost any other name in the universe.
The bull case centres on zovegalisib's Phase 2 data in PIK3CA-driven vascular anomalies, where the 60% volumetric response rate positioned the drug as a credible candidate for accelerated approval. Bears counter that clinical-stage biotechs are perpetually exposed to dilution risk and that tolerability questions at higher doses could limit the commercial addressable market. Insider activity adds a note of caution: the CEO, CFO, and several other senior executives sold shares through June and July, totalling nearly $7.5 million net over 90 days. These were small in percentage terms — under 0.003% of shares per transaction — but the pattern is consistent and comes as the stock trades near recent highs following a year-to-date gain of over 130%.
Tonight's print is therefore less a test of pipeline excitement — the Street is already bought in — and more a test of whether management's financial guidance and clinical update on zovegalisib's dose-selection strategy can justify a valuation that even the bulls are still stretching to reach.
See the live data behind this article on ORTEX.
Open RLAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
